BeOne Medicines Ltd. - Sponsored ADR (ONC)
(Real Time Quote from BATS)
$297.79 USD
-9.44 (-3.07%)
Updated Aug 6, 2025 03:12 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, BeOne Medicines Ltd. - Sponsored ADR has a market cap of $33.67B, which represents its share price of $307.23 multiplied by its outstanding shares number of 109.60M. As a large-cap company, ONC's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ONC 297.79 -9.44(-3.07%)
Will ONC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
ONC: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
Other News for ONC
BeOne Medicines Ltd. 2025 Q2 - Results - Earnings Call Presentation
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
ONC Reports Q2 Revenue Surpassing Expectations, Reinforcing Growth Trajectory